# **RESEARCH ARTICLE**



# Single-cell transcriptomic analysis reveals a decrease in the frequency of macrophage-RGS1<sup>high</sup> subsets in patients with osteoarticular tuberculosis

Ying Jiang<sup>1†</sup>, Xinqiang Zhang<sup>2†</sup>, Bo Wang<sup>1</sup>, Liping Tang<sup>1</sup>, Xin Liu<sup>1</sup>, Xiudong Ding<sup>1</sup>, Yueming Dong<sup>1</sup>, Hong Lei<sup>1\*</sup>, Di Wang<sup>3\*</sup> and Huicheng Feng<sup>1\*</sup>

## **Abstract**

**Background** Cell subsets diferentially modulate host immune responses to *Mycobacterium tuberculosis* (MTB) infection. However, the nature and functions of these subsets against osteoarticular tuberculosis (OTB) are unclear. Here, we aimed to understand the phenotypes and functions of immune cell subsets in patients with OTB using single-cell RNA sequencing (scRNA-Seq).

**Methods** Pathological and healthy adjacent tissues were isolated from patients with OTB and subjected to scRNA-Seq. Unsupervised clustering of cells was performed based on gene expression profles, and uniform manifold approximation and projection was used for clustering visualization.

**Results** Thirteen cell subsets were identifed in OTB tissues. scRNA-seq datasets of patients and healthy controls (HCs) showed that infection changed the frequency of immune cell subsets in OTB tissues. Myeloid cell examination revealed nine subsets. The frequency of macrophage-RGS1<sup>high</sup> subsets decreased in OTB tissues; this increased MTB susceptibility in an SLC7A11/ferroptosis-dependent manner. Immunohistochemistry assays and fow cytometry for patients with OTB and osteoarticular bacterial infection (OBI) and HCs verifed that the frequency of macrophage-RGS1<sup>high</sup> subset decreased in OTB tissues and blood samples, thereby distinguishing patients with OTB from HCs and patients with OBI.

**Conclusion** The macrophage-RGS1<sup>high</sup> subset levels were decreased in patients with OTB, and would be up-regulated after effective treatment. Therefore, the clinical significance of this study is to discover that macrophage-RGS1high subset may serve as a potential biomarker for OTB diagnosis and treatment efficacy monitoring.

**Keywords** Osteoarticular tuberculosis, scRNA, Biomarker, Macrophages, Ferroptosis

† Ying Jiang and Xinqiang Zhang have contributed equally to this study.

\*Correspondence: Hong Lei leihong\_hospital@126.com Di Wang wangdi\_42869@163.com Huicheng Feng fenghc309@126.com Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/.](http://creativecommons.org/licenses/by/4.0/)

## **Introduction**

Extra-pulmonary tuberculosis (EPTB) accounts for 15–20% of all *Mycobacterium tuberculosis* (MTB) infections. However, the rates of diagnosis and treatment of EPTB are considerably lower than those of pulmonary tuberculosis (PTB) because no reliable diagnostic markers are available (Sharma et al. [2021\)](#page-13-0). Furthermore, osteoarticular tuberculosis (OTB) accounts for 10–18% of all EPTB cases (Khan et al. [2021\)](#page-13-1). OTB symptoms are often non-specifc, presenting long before suspected diagnosis. Despite advances in examination methods, OTB diagnosis remains difficult and time-consuming. Diagnosis typically relies on bacteriological and/or histopathological confrmation of MTB in the afected area (Jia et al. [2013](#page-13-2)). Rapid diagnosis is crucial for early initiation of anti-OTB chemotherapy, which can reduce disability and functional impairment.

Whole-genome sequencing technology can be used to identify specifc markers of PTB and clarify the immune mechanisms (Singhania et al. [2021](#page-13-3); Cai et al. [2020](#page-13-4)). Compared to bulk RNA sequencing (RNA-Seq), which provides only the average expression signal for millions of cells, single-cell RNA sequencing (scRNA-Seq) allows simultaneous analysis of > 10,000 single-cell transcriptomes and characterization of novel cell subsets (Cai et al. [2020](#page-13-4)). scRNA-Seq can reliably identify closely related cell populations, reveal changes that render each individual cell type unique, and elucidate the heterogeneity of gene expression patterns in peripheral blood cell populations in healthy individuals and patients (Chen et al. [2021a,](#page-13-5) [b](#page-13-6), [c\)](#page-13-7). Changes in subpopulation distribution and heterogeneity of blood immune cells in pulmonary tuberculosis have been detected using scRNA-Seq (Cai et al. [2020](#page-13-4)). However, scRNA-Seq analysis of OTB cases has not been reported. In this study, we subjected pathological tissues (PTs) and healthy adjacent tissues (ATs) from patients to scRNA-Seq for delineating the transcriptomic profles of individual immune cell subsets.

## **Methods**

## **Clinical samples**

Tissue and blood samples from patients who had visited the Eighth Medical Center of the Chinese PLA General Hospital (Beijing, China) during 2020–2022 were used in the study. The diagnostic criteria for OTB (Wang et al. [2020](#page-13-8)) were as follows: patients with (i) typical symptoms of tuberculosis infection, including mild fever, night sweats, weight loss, and fatigue; (ii) MTB antibody positivity; (iii) tuberculosis granuloma; and (iv) typical features of OTB on imaging. Patients with other immune and neoplastic diseases or HIV infection were excluded. The first cohort comprised three patients with OTB. The PTs and ATs (distance from PT lesion: 3 cm) of each patient were divided into two parts. One part was used for 10×genomics scRNA-Seq and the other was used for subsequent analysis. Supplementary Table 1 provides detailed information on scRNA-Seq analyses of these samples and the clinical features of donors. The second cohort comprised 27 patients with OTB (including the 3 patients in the frst cohort); their PTs and ATs were used for specifc analyses. Age- and sex-matched healthy volunteers  $(n=27)$  and patients with osteoarticular bacterial infections (OBI;  $n=27$ ) were included as controls. Blood samples from all included participants were collected on the 1st day of their enrolment. The clinical features of all included participants in the second cohort are shown in Supplementary Table 2. All patients with OTB were examined using CD68 staining, tuberculosis DNA typing, and culturing.

This study was approved by the Eighth Medical Center of the Chinese PLA General Hospital, Beijing, China (ref no. 309202201041537). All experiments and sampling were conducted in accordance with the approved institutional guidelines for ethical and biosafety protocols. Written informed consent was obtained from all participants.

#### **Single‑cell RNA sequencing**

Details of scRNA-Seq and subsequent bioinformatic analysis, which were performed as described previously (Macosko et al. [2015;](#page-13-9) Satija et al. [2015;](#page-13-10) Butler et al. [2018](#page-13-11); Zhang et al. [2020\)](#page-13-12), are presented in the Supplementary Text.

## **Molecular validation**

Multiple molecular methods were used for subsequent validation, as described previously (Wang et al. [2022](#page-13-13); Liu et al. [2014](#page-13-14); Chen et al. [2021a,](#page-13-5) [b](#page-13-6), [c](#page-13-7)). Detailed protocols are described in the Supplementary Text.

## **In vivo osteoarticular tuberculosis model**

The in vivo osteoarticular tuberculosis model was constructed according to a previous report (Zhou et al. [2018](#page-13-15)). New Zealand rabbits were randomly divided into two groups. An artifcial bone defect was created on the femoral condyle and contaminated with 0.1 mL a tubercle bacilli suspension containing  $10^6$  colony forming units (CFUs). After 7 days, the rabbits were treated with an RGS1 inhibitor (CCG-63808, 0.05 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) via intraperitoneal injection every 2 days. After 4 weeks, blood was collected from the rabbits, which were subsequently sacrifced. One part of the infected tissue was used for hematoxylin and eosin (H&E) staining or cytokine measurement and the other part was homogenized and plated on Middlebrook 7H10 agar medium (262,710; BD Biosciences) to determine the CFUs.

## **General statistical analysis**

Data are expressed as mean±standard deviation. All experiments were performed in no less than triplicate. All statistical analyses were performed using SPSS 24.0 software (SPSS) and GraphPad (Prism 8.0, GraphPad). Descriptive data were summarized as mean (SD). The diference between two group were compared using Student's t-test for continuous variables and using Pearson's Chi-square test for discrete variables. If any continuous variables were non-parametric, Mann–Whitney U-test was employed. Statistical significance was set at  $p < 0.05$ . Receiver operating characteristic (ROC) curves were used to evaluate the performance of the diagnostic test.

#### **Results**

## **scRNA‑Seq analysis resolved major cell types in human OTB**

To determine the cellular composition of human OTB, we conducted scRNA-Seq analysis (10×Genomics Chromium System) of cells on the PTs and ATs from three patients with OTB in the frst cohort (Fig. [1](#page-3-0)A). Detailed clinical information on the collected samples is provided in Supplementary Table 1. The three patients were diagnosed with OTB based on their medical history, imaging results (Supplementary Fig. 1A–C), bacteriological examinations, and histopathological examinations (Supplementary Fig. 2A–C). Quality control statistical results of the fltered data are shown in Supplementary Table 3. Sequencing quality distribution and base distribution checks showed that the fltered data were qualifed and could be used for subsequent analysis (Supplementary Fig. 3A, B).

The UMAP plot revealed a high clustering of cells across the OTB PTs and ATs from each patient (Fig. [1](#page-3-0)B, left). SingleR was used for automatic annotation of major cell types, and it revealed 13 distinct cell clusters across all included participants (Fig. [1](#page-3-0)B right, C). As key immune clusters, macrophages and monocytes expressed LYZ, T cells expressed CD2 expression, and B cells expressed DERL3 (Fig. [1D](#page-3-0)), which are the known markers for the indicated cell types. Also, we identifed a series of transcripts that are specifcally expressed in specifc immune cell types: C1QC, AIF1, CCL3, and HLA-DQA1 for macrophages and monocytes (Supplementary Fig. 4A); CCL5, GZMK, IL-7R, and TUBA4A for T cells (Supplementary Fig. 4B); and FKBP11 and MZB1 for B cells (Supplementary Fig. 4C). Specifc expressed transcripts for other cell types were also identifed (Supplementary Fig. 5A, B). Based on these annotations, we calculated the proportion of each cell type in PTs group and ATs group ([F](#page-3-0)ig.  $1E$  $1E$ , F). Fibroblasts represented the largest fraction of all annotated cells. Macrophages and monocytes accounted for the greatest proportion of infltrating immune cells, followed by T and B cells (Fig. [1E](#page-3-0)). Small clusters of dendritic cells (DCs) and neutrophils were also observed. T cells and macrophages showed a signifcantly higher frequency in the PT group than in the AT group (Fig. [1F](#page-3-0);  $p < 0.05$ ). B cells were not annotated in ATs. Only a small cluster of B cells was annotated in PTs, suggesting that B cells might play a secondary role in anti-MTB infection, which aligns with the fndings of a previous study (Cai et al. [2020](#page-13-4)). Notably, the number of fbroblasts in the PT group was markedly lower than that in the AT group. Further research is needed to elucidate the molecular mechanisms underlying this phenotype (Fig. [1F](#page-3-0)).

## **scRNA‑Seq identifed eight T and natural killer cell subsets and three B cell subsets**

T and natural killer (T&NK) cells play a critical role in controlling MTB infection in patients with MTB (Cai et al. [2020](#page-13-4)). Therefore, we further explore the phenotypic diferences in T&NK between PTs group and ATs group. First, we identifed eight T&NK cell subsets based on singleR automatic annotation (Fig.  $2A$  and  $B$ ). The UMAP analysis revealed that the T&NK cell subsets in PTs presented strong heterogeneity compared with those in ATs, and the clustering was similar among diferent patients, indicating that they exhibited high clustering by source rather than by individuals (Fig. [1C](#page-3-0)). Among the 8 subsets, 4 were CD8+T cell subsets, including CD8+Trm, CD8+Tem, CD8+Tm, and CD8+Temra; 2 were CD4+T cell subsets including  $CD4+Tn$ aive and  $CD4+Trm$ . The other two clusters were naïve Treg cells and NK subset. HSPA1B (CD8+Trm), CD8A (CD8+Tem), ANXA1 (CD8+Tm), CCR7 (CD4+Tnaive), CD52 (D4+Trm), BATF (naïve Treg) and AREG (NK) were found to have the most specifc expression characteristics in their respective specifc cell subtypes, and their expression distributions were shown in Fig. [2D](#page-4-0).

The proportions of the eight T&NK cell subsets are shown in Fig.  $2E$  $2E$ , [F.](#page-4-0) CD8 + Trm accounted for the highest proportion (29.72%), followed by CD8+Tem (22.63%),  $CD8 + Tm (17.46%)$ , and  $CD4 + Tnaive (10.25%).$  The proportions of these subsets varied between the PTs and ATs. Predictably, most subtypes were more prevalent in PTs than in ATs. Specifcally, CD8+Tm was lower in PTs than in ATs (Fig. [2](#page-4-0)F). GSVA revealed that CD8+Tm cells exhibited a low rate of nearly all signaling, suggesting that these cells were not activated (Fig. [2G](#page-4-0)).

Although the cluster of B cells was small, we identified three B cell subsets (Supplementary Fig. 6A–C), including memory B cells highly expressed



<span id="page-3-0"></span>**Fig. 1** Single-cell transcriptional profling of OTB PTs and ATs in the frst cohort. **A** Schematic representation of the experimental workfow for defning and comparing OTB PTs and ATs. **B** Left: UMAP plot of cells from T1, T2, T5, T6, T7, and T8 samples. Right: UMAP of a single-cell profle, with each cell color-coded for its associated cell type. **C)** Heat map showing the expression of marker genes in the indicated cell types. **D** Top: UMAP plot showing the expression of marker genes for macrophages/monocytes, T cells, and B cells defned above each panel. Bottom: The expression of known T&NK cell type-discriminating genes. **E** Proportion of the fraction of cells for the 13 cell types in OTB PTs and ATs. **F** Box plot showing the fraction of the 13 cell types in OTB PTs and ATs. *PT* OTB pathological tissue, *AT* OTB adjacent tissue

HSPA1B, IGA+plasma highly expressed IGHA2, and IGG+plasma highly expressed (Supplementary Fig. 6D). The clustering and proportion of the three cell subtypes were similar, both by source and individual (Supplementary Fig. 6C, E). GSVA revealed the specific signaling pathway of the three B cell subtypes, which might be valuable for future analyses (Supplementary Fig. 6F).

**scRNA‑Seq identifed nine macrophage/monocyte subsets**

MTB infection induces the accumulation of myeloid cells that express high levels of infammatory markers (Cai et al. [2020](#page-13-4)). This study also showed that myeloid cells, including macrophages, monocytes, neutrophils, and DCs, were the largest immune cell group in OTB tissues. Therefore, the annotation and analysis of myeloid cells were the main focus of this study. Using several recently reported markers (Chen et al. [2021a](#page-13-5), [b,](#page-13-6) [c;](#page-13-7) Zou et al. [2021](#page-13-16)), we identifed nine clusters in the myeloid lineage expressing specifc marker genes (Fig. [3](#page-6-0)A, [B\)](#page-6-0): 4 clusters of macrophages (macrophages-CCL20<sup>high</sup>, macrophage-RGS1<sup>high</sup>, M1 macrophage, and all other macrophages), 2 clusters of neutrophils (neutrophils-S100Phigh and neutrophils-IL1Bhigh), 2 clusters of DCs (conventional DCs and plasma cytoid DCs), and 1 cluster of proliferating cells. The uniform manifold approximation analysis of samples revealed that the myeloid cell subsets in PTs presented strong heterogeneity compared with those in ATs, and the clustering was similar among diferent patients, indicating that they exhibited high clustering by source rather than by individuals (Fig.  $3C$ ). The clusters of these subsets and their markers are shown in Fig. [3](#page-6-0)D. In addition to CCL20, macrophages-CCL20high were also enriched for CCL18. Macrophages-RGS1<sup>high</sup> expressed high levels of F13A1, which was new for this subset. Neutrophils-S100Phigh was enriched for S100A9 and neutrophils-IL1Bhigh expressed high levels of SERPINB2. M1 macrophages, which are recruited during MTB infection (Nguyen et al. [2021\)](#page-13-17), were confrmed to express high levels of TNF  $l$  (Ren et al. [2021](#page-13-18)). The proportion of all myeloid cells in PTs and ATs is shown in Fig. [3E](#page-6-0). Macrophages-CCL20high and macrophages-RGS1high accounted for the highest proportion of macrophages (Fig.  $3E$ ). The frequency of most myeloid cells was markedly higher in the PT group than in the AT group (Fig. [3F](#page-6-0)). Interestingly, macrophage-RGS1<sup>high</sup> frequency decreased in the PT group, warranting further explora-tion (Fig. [3F](#page-6-0)). GSVA showed that macrophages- $RGS1^{nigh}$ downregulated various infammatory signaling pathways compared to M1 polarized macrophages (Fig. [3](#page-6-0)G).

We determined the diferentially expressed transcripts in all myeloid cells between the PT and AT groups to study their role in patients with OTB. The data obtained from this analysis were extensive; therefore, we have provided only the fndings for all annotated myeloid cells (data for other cells are not shown), including heat map, volcano plot, bubble map, Gene Ontology (GO) analysis results, and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis results (Fig. [4](#page-7-0)A–G). We focused on the macrophage-RGS1<sup>high</sup> subsets because they are specially distributed in OTB tissues. Furthermore, the diferentially expressed genes (DEGs) in the macrophage-RGS1<sup>high</sup> subsets were different from other subsets, such as macrophages-CCL20 $h$ <sup>igh</sup> and M1 macrophages (Fig. [4](#page-7-0)D), suggesting a specifc role of the macrophage-RGS1high subsets against OTB. Among the top diferentially expressed target genes in the macrophage- $RGS1^{high}$ subsets (Fig. [4](#page-7-0)H), SLC7A11, the key inhibitor of ferroptosis, was highly expressed in the PTs group.

## **RGS1 increased both ferroptosis and the intracellular killing ability of macrophage**

As the above results suggested the importance of RGS1 in the function of macrophages against MTB, we transfected RGS1 small interfering RNA (siRNA) (named RGS1-KD) into cultured THP-1-derived macrophages, followed by H37Rv infection at a multiplicity of infection (MOI) of 10 for 24 h. Western blotting demonstrated that H37Rv infection could signifcantly enhance RGS1 expression, and RGS1 expression was down-regulated under RGS1-KD treatment (Fig. [5A](#page-7-1)). Meanwhile, we confrmed that the SLC7A11 level was also enhanced in MTB infected macrophages. Interestingly, the RGS1- KD treatment induced the SLC7A11 expressions in both H37Rv infected and un-infected macrophages, indicating that RGS1 inhibited the SLC7A11 expressions (Fig. [5](#page-7-1)A).

As we know, SLC7A11 is a negative marker of fer-roptosis (Koppula et al. [2021\)](#page-13-19). Therefore, we speculated that by SLC7A11 down-regulation, RGS1 might induce ferroptosis of macrophages. To verify our hypothesis, RGS1-KD-treated and control macrophages were challenged with H37Rv at an MOI of 10 for 24 h. We found that the ferroptosis markers, such as the relative iron and MDA levels were increased by H37Rv infection, and their levels were lower under RGS1-KD treatment (Fig. [5B](#page-7-1), [C](#page-7-1)). H37Rv infection could induce cell necrosis, and the level was lower under RGS1-KD treatment. Treatment with

<sup>(</sup>See fgure on next page.)

<span id="page-4-0"></span>**Fig. 2** T&NK cell clusters in OTB PTs and ATs in the frst cohort. **A** UMAP of a single-cell profle with each cell color-coded for its associated T&NK cell type. **B** Heat map showing the expression of marker genes in the indicated cell types. **C** UMAP plot of T&NK cell types from T1, T2, T5, T6, T7, and T8 samples. **D** Top: UMAP plot showing the expression of marker genes for the T&NK subsets; bottom: The expression of known T&NK cell type-discriminating genes. **E** Proportion of the fraction of T&NK subsets. **F** Box plot showing the fraction of T&NK subsets in OTB PTs and ATs. **G** Diferences in pathway activities scored per cell analyzed using GSVA between the diferent T&NK subsets. *PT* OTB pathological tissue, *AT* OTB adjacent tissue



**Fig. 2** (See legend on previous page.)



<span id="page-6-0"></span>**Fig. 3** Myeloid clusters in OTB PTs and ATs in the frst cohort. **A** UMAP of a single-cell profle, with each cell color-coded for its associated myeloid cell type. **B** Heat map showing the expression of marker genes in the indicated cell types. **C** UMAP plot of myeloid cell types from T1, T2, T5, T6, T7, and T8 samples. **D** Top: UMAP plot showing the expression of marker genes for the myeloid subsets; bottom: The expression of known myeloid type-discriminating genes. **E** Proportion of the fraction of myeloid subsets. **F** Box plot showing the fraction of nine myeloid cell types in OTB PTs and ATs. **G** Diferences in pathway activities scored per cell via GSVA between the diferent myeloid subsets. *PT* OTB pathological tissue, *AT* OTB adjacent tissue



<span id="page-7-0"></span>**Fig. 4** Diferentially expressed genes in macrophage-RGS1high subsets between PTs and ATs in the frst cohort. **A** Heat maps. **B** Bubble Chart. **C** Volcano plot displaying the upregulated and downregulated genes in macrophage-RGS1high subsets between in OTB PTs and ATs. **D** Venn plot displaying the overlapped upregulated and downregulated genes among macrophage-RGS1<sup>high</sup> subsets, macrophages-CCL20<sup>high</sup> subsets, and M1 macrophages subsets. **E** GO term column of the genes described in (A-C). **F** Directed acyclic graphs (DAGs) for the GO term described in (E). **G** KEGG pathway term scatter diagram of the genes described in (**A**‒**C**). **H** Violin plots showing the top diferentially expressed target genes in macrophage-RGS1<sup>high</sup> subsets between OTB PTs and ATs

Fer-1 (a ferroptosis inhibitor) decreased the cell necrosis rate in both RGS1-KD-treated and control macrophages and could eliminate the diference between these groups

(Fig.  $5D$  $5D$ ). These results confirm our speculation that RGS1 could induce the ferroptosis of macrophages.

(See fgure on next page.)

<span id="page-7-1"></span>**Fig. 5** Function of RGS1 on the MTB infection in vitro and in vivo. **A**–**C** THP-1-derived macrophages were transfected with RGS1 siRNA (RGS1-KD) and the negative control (RGS1-NC) for 24 h, and then challenged with H37Rv (MOI at 10:1) for 24 h. **A** RGS1 and SLC7A11 levels were determined using western blot assay. **B** Relative iron levels were determined using an iron assay kit. **C** Relative MDA levels were determined using a lipid peroxidation assay kit. **D** THP-1-derived macrophages subjected to RGS1-NC or RGS1-KD treatment were challenged with H37Rv (MOI at 10:1) for 24 h, with or without fer-1 pre-treatment at 2 μM; then, cell necrosis was determined using PI staining followed by fow cytometry analysis. **E** THP-1-derived macrophages subjected to RGS1-NC or RGS1-KD treatment were challenged with H37Rv (MOI at 10:1) for 24 h, with or without fer-1 pre-treatment at 2 μM; then, CFUs were quantifed in supernatants pooled with cell lysates. **F–J** OTB rabbit models were treated with or without the RGS1 inhibitor CCG-63808 at 0.05 mg/kg via intraperitoneal injection every 2 days. **F** Histopathology of the tissues was assessed via H&E staining. Left: Representative feld of the PT tissues; Right: infammatory areas were calculated from the PT tissues. **G–I** Relative (**G**) SLC7A11 mRNA levels; (H) TNFα mRNA levels, and (I) IL-6 mRNA levels in the PTs. **J** MTB CFUs in PTs were determined



Ferroptosis was reported to promote bacterial dissemination and tissue damage under MTB infection (Amaral et al  $2019$ ). Therefore, we next explored the regulatory role of RGS1 against MTB infection. RGS1-KD-treated and control macrophages were challenged with H37Rv at an MOI of 10 for 24 h. Interestingly, the total survival rate of bacteria was signifcantly higher in the RGS1-KD group than in the control, whereas Fer-1 could decrease the bacterial load (Fig.  $5E$  $5E$ ). These results indicated that RGS1 might promote ferroptosis (bacterial dissemination and tissue damage promoter) as well as MTB killing simultaneously.

We next assessed the efects of RGS1 in the OTB rabbit model. The rabbits were infected with H37Ry to construct an OTB model, with or without CCG-63808 (RGS1 inhibitor) treatment, for 4 weeks. We successfully detected H37Rv in each infected tissue, indicating that an infection model was successfully constructed. Histological examination (Fig. [5F](#page-7-1)) and qRT-PCR assay confrmed that the efect of RGS1 inhibition was associated with reduced tissues infammatory damage, which was refected by infammatory area, infammatory factor levels, and enhanced SLC7A11 expressions (Fig. [5G–I](#page-7-1)). And, measurement of MTB CFU in the PTs of the CCG-63808-treated OTB rabbit revealed a marked and highly signifcant enhancement in bacterial load, compared with that in the untreated controls (Fig.  $5$ J). These results indicated that RGS1 can promote both infammatory tissue damage and sterilization in vivo.

## **Validation of low frequency of macrophage‑RGS1high subsets in human OTB tissues**

Next, clinical samples from the second cohort were used to assess the effects of macrophage-RGS1<sup>high</sup> subsets on patients with OTB. First, immunofuorescence analysis of CD14 (macrophage marker) and RGS1 was performed. Cells co-localizing with RGS1 and CD14 were macrophage-RGS1<sup>high</sup> subsets. The expression of macrophage-RGS1<sup>high</sup> subsets was mainly downregulated in PTs compared with that in the AT regions (Fig. [6](#page-9-0)A,  $B$ ; p<0.05). RGS1 was also expressed in cells other than



<span id="page-9-0"></span>**Fig. 6** Diference in macrophage-RGS1high subsets between PTs and ATs in patients with OTB in the second cohort. **A**, **B** RGS1 (red) and CD14 (green) in individual and merged channels were determined using IF in the PTs and ATs from patients with OTB (n=27) in the second cohort. **A** Representative IF feld of vision. **V** Quantifcation of merge counting (CD14+RGS1+) in the PTs and ATs from patients with OTB (n=27) in the second cohort. **C**, **D** RGS1 staining in the PTs and ATs from patients with OTB (n=27) in the second cohort was determined using IHC. **C** Representative immunohistochemical feld of vision. **D** Quantifcation of RGS1 staining in the PTs and ATs from patients with OTB (n=27) in the second cohort

macrophages. Overall, RGS1 expression was signifcantly lower in PTs, as confrmed by the results of the IHC assay (Fig.  $6C$ , [D;](#page-9-0)  $p < 0.05$ ). These results are in accordance with the scRNA data.

## **Low frequency of macrophage‑RGS1high subsets in blood samples diferentiated patients with OTB and those with OBI**

We determined the phenotypes of macrophage-RGS1<sup>high</sup> subset in the blood of patients with OTB using flow cytometry to explore whether this subset could act as a potential biomarker. The frequency of macrophage-RGS1high subsets in blood samples was also lower in individuals with OTB than in HCs (Fig. [7A](#page-10-0), [B\)](#page-10-0). Meanwhile, the frequency of macrophage- $RGS1<sup>high</sup>$  subsets appeared to be slightly higher in patients with OBI than in HCs, although the diference was not signifcant (Fig. [7B](#page-10-0)). The ROC curve analyses of patients with OTB vs. HCs and patients with OTB vs. those with OBI indicated that the macrophage-RGS1 $h$ igh subset could serve as a valuable biomarker, with the area under the curve being 0.[7](#page-10-0)894 (Fig. 7c, left; OTB vs. HCs,  $p = 0.003$ ) and 0.8587 (Fig. [7C](#page-10-0), right; OTB vs. OBI, p < 0.001), respectively. The macrophage-RGS1 $h$ igh subset frequency in blood samples did not vary signifcantly between hip OTB cases and knee OTB cases (Fig.  $7D$ ;  $p > 0.05$ ). Among all these patients with OTB, compared to acidfast bacilli (AFB)-negative cases, AFB-positive cases showed significantly low macrophage-RGS1<sup>high</sup> subset frequency in tissue samples (Fig. [7](#page-10-0)E; p < 0.05). We further analyzed the frequency of the macrophage-RGS1<sup>high</sup> subset in blood samples after anti-OTB treatment. The macrophage-RGS1<sup>high</sup> subset frequency increased 8 weeks after initiating treatment (Fig. [7](#page-10-0)F). These results indicate that macrophage-RGS1 $h$ <sup>igh</sup> is useful for diferentiating patients with OTB from HCs and



<span id="page-10-0"></span>**Fig. 7** Low macrophage-RGS1high subset frequency differentiates patients with OTB from HCs and patients with OBI. Macrophage-RGS1high subsets were determined using fow cytometry analysis in blood samples in the second cohort. **A** Representative scatter diagram of fow cytometry analysis. **B** Comparison of the frequency of macrophage-RGS1<sup>high</sup> subsets in blood samples among patients with OTB, patients with OBI, and HCs. **C** Left: ROC curve for macrophage-RGS1high subsets to distinguish patients with OTB from HCs; right: ROC curve for macrophage-RGS1high subsets to distinguish patients with OTB from those with OBI. **D** Comparison of the frequency of macrophage-RGS1<sup>high</sup> subsets in blood samples from 13 hip infection cases and 14 knee infection cases. **E** Comparison of the frequency of macrophage-RGS1<sup>high</sup> subsets in blood samples from 9 AFB+cases and 18 AFB- cases. **F** Comparison of the frequency of macrophage-RGS1high subsets in blood samples from 27 patients with OTB before and after 8 weeks of anti-MTB treatment. *OTB* osteoarticular tuberculosis, *OBI* osteoarticular bacterial infection, *HC* healthy controls

patients with OBI and might help indicate the treatment outcome of OTB.

## **Discussion**

Current diagnostic methods for OTB include radiological tests combined with histopathological techniques, and microbiological results. However, these methods all have shortcomings. The radiological tests and histopathological tests lack sensitivity and specifcity to provide an early diagnosis. For microbiological tests, clinical specimens are usually assessed using AFB smear, which is the fastest diagnostic test, but only 20–40% of clinical specimens test positive. MTB culturing also lacks sensitivity and takes a long time to obtain results (Jia et al. [2013\)](#page-13-2). In recent years several commercial nucleic acid amplifcation tests, like Mycobacterial PCR and gene Xpert, have been developed for quickly identifying pathogenic MTB, but they cannot determine the activity of the pathogen (Fernandez-Pittol et al. [2021\)](#page-13-21). Progression of the active MTB disease is almost universally regarded as a 'failure' of the host's immune system to control the infection. This process is usually accompanied by the molecular dysregulation of the critical balance between the immune cells and MTB (Wang et al.  $2022$ ). Therefore, identifying specifc cell subsets in patients caused by MTB infection has the potential implications on the clinical diagnosis and treatment strategies. For example, Sun et al. reported that the cell population data could assist the distinguish of active tuberculosis and community-acquired pneumonia (Sun et al. [2021](#page-13-22)). Cai et al. identifed that the frequency of CD3-CD7+GZMB+in peripheral blood could be used as a novel biomarker for distinguishing PTB from latent tuberculosis infection (LTBI) (Cai et al. [2020\)](#page-13-4). In the present study, we aimed to elucidate the effect of MTB infection on PTs using scRNA-Seq of OTB tissues and the adjacent HC tissues. We distinguished 13 major cell types and sub-clustered myeloid cells into nine subsets based on quantitative gene expression. The most noteworthy cell type included macrophage-RGS1<sup>high</sup> subsets, because their frequency was signifcantly decreased in OTB tissues, whereas the frequency of other subtypes was typically increased.

RGS1 is a regulatory member of the G protein signaling family that links G protein-coupled receptors with calcium signaling. It is specifcally expressed in macrophages, T cells, and B cells. RGS1 dysregulation may lead to various autoimmune diseases (Patel et al. [2015](#page-13-23); Feng et al. [2021\)](#page-13-24). Patel et al. reported that vascular infammation condition in atherosclerosis increases RGS1 expression (Patel et al. [2015\)](#page-13-23). Also, RGS1 has been indicated to be a new marker and promoting factor for CD8+T cell exhaustion in tumors (Bai et al. [2021](#page-13-25)). RGS1 inhibits chemokine-induced lymphocyte migration

because chemokine-dependent activation of G proteincoupled receptors can activate heterotrimeric G protein subunits, resulting in enhanced cell migration and adhesion (Bai et al. [2021\)](#page-13-25). We further found that expressions of RGS1 across the Cancer Genome Atlas Program (TCGA) tumors were generally enhanced, compared with the normal controls (data not shown). Therefore, it can be seen that the expression patterns of RGS1 in OTBs is opposite to that in the OBIs, vast majority of infammatory diseases or tumors, which is one of the reasons why it is suitable as a diagnostic marker for OTBs. Of course, RGS1 is down-regulated in some tumors such as bladder cancer, rectum adenocarcinoma, and thyroid carcinoma (from TCGA databank), which can interfere with its use as a biomarker for the diagnosis of OTB. Therefore, exploring a diagnostic strategy that combines RGS1 levels with existing diagnostic methods to improve the sensitivity and specifcity of OTBs detection should be one of the next research directions.

In the present study, several genes related to cell adhesion were diferentially expressed between PTs and ATs in macrophage-RGS1<sup>high</sup> subsets, suggesting that the function of macrophage-RGS1high subsets is altered by MTB infection. SLC7A11 expression was only upregulated in macrophage-RGS1<sup>high</sup> subsets in PTs at the single-cell level. SLC7A11 imports cysteine for glutathione biosynthesis and antioxidant defense and is overexpressed in multiple human and immune diseases (Koppula et al. [2021](#page-13-19)). SLC7A11 overexpression partially suppresses ferroptosis, a form of regulated cell death induced by excessive lipid peroxidation (Lang et al. [2019\)](#page-13-26). MTB infection has been found to induce ferroptosis (Amaral et al. [2019](#page-13-20)). In the present study, upregulated SLC7A11 expression were observed in macrophage-RGS1<sup>high</sup> subsets under MTB infection, suggesting the functionality of macrophage-RGS1<sup>high</sup> may be related to SLC7A11 and ferroptosis. Correspondingly, we confrmed that RGS1 can inhibit the expression of SLC7A11. However, the function of SLC7A11 and the process of ferroptosis against intracellular MTB are complex. It has been reported that MTB infection can upregulate not only ferroptosis but also the expression of the ferroptosis blocker SLC7A11 (Amaral et al. [2019](#page-13-20)). Meanwhile, in the present study, fer-1, a ferroptosis inhibitor through antioxidant efects, was found to inhibit MTB sensitivity; This finding indicates that the regulatory efect of SLC7A11 on MTB is diferent from that of ferroptosis. Cai et al. found that SLC7A11 mainly exerts bactericidal effect in tuberculosis through the TLR2/Akt- and p38-dependent signaling pathway, which is diferent from the ferroptosis pathway (Cai et al.  $2016$ ). The present study showed that the effect of RGS1 against MTB is also through the opposite direction to ferroptosis.

We also explored the correlation between macrophage-RGS1high subset frequencies and clinical indicators in patients with OTB. The decrease in macrophage-RGS1high subset frequency was further verified using tissue and blood samples. Considering that this result is not consistent with the in vitro and in vivo experimental results (MTB induces RGS1 expression), we speculate that there are diferences in the expression of RGS1 at diferent stages of infection, attributable to the dynamics of the competition between MTB immune escape and host immune killing.

Further exploration demonstrated that the change in peripheral macrophage-RGS1<sup>high</sup> subset frequency was sensitive and specifc for discriminating patients with active OTB infection from HCs and patients with OBI. As blood is the most readily accessible sample in humans, we propose that macrophage-RGS1<sup>high</sup> subsets could be used as biomarkers in patients with OTB. Moreover, 8 weeks of treatment can increase macrophage-RGS1<sup>high</sup> subset frequency, suggesting that macrophage-RGS1<sup>high</sup> subsets may also be used to monitor treatment outcomes.

Overall, the macrophage-RGS1 $h$ igh subset could be used as a biomarker for distinguishing patients with OTB from patients with OBI and HCs.

This study has some significance as well as limitations. Firstly, to our best knowledge, this is the frst to provide scRNA-Seq data for OTB tissues. However, we only analyzed the role of main immune cell subtypes (myeloid cells, T cells, and B cells). In fact, as shown in Fig. [1](#page-3-0)F, among all the annotated cell types, fbroblasts showed the greatest diferential changes between the PTs group and the ATs group, indicating the potential function. Therefore, another future direction based on this study should be to explore the functions of more cell subtypes in the progression of OTB, which might accelerate the discovery of more biomarkers and therapeutic targets on OTB. Further, we should obtain the scRNA-Seq data on the tissues from non-OBT controls (such as healthy controls or OBI controls), in order to avoid potential biases. Secondly, the current conclusions on macrophage- $RGS1<sup>high</sup>$ subset function are based on a small-scale study. In the next step, larger-scale multicenter studies to eliminate the infuence of regional diferences or medical conditions are needed.

#### **Abbreviations**





## **Supplementary Information**

The online version contains supplementary material available at [https://doi.](https://doi.org/10.1186/s10020-024-00886-9) [org/10.1186/s10020-024-00886-9](https://doi.org/10.1186/s10020-024-00886-9).

Additional fle 1: Figure 1 Imaging diagnosis results of the three patients in the frst cohort. Figure 2 H&E staining and CD68 immunohistochemistry results of the OTB lesion tissue from (A) Patient 1, (B) Patient 2, and (C) Patient 3 in the frst cohort. Figure 3 Quality control of single-cell sequencing data. Figure 4. Novel markers for macrophages/monocytes, T cells, and B cells and their clustering. Figure 5 Novel markers for specifc myeloid cell subtypes and their clustering. Figure 6 B cell clusters in OTB PTs and ATs in the frst cohort. Table 1. Detailed information of samples collected for scRNA-Seq analyses in the study. Table 2. Clinical characteristics of included participants in the second cohort. Table 3. Cell number and gene median statistics. Methods

#### **Author contributions**

YJ, LT, and XZ performed scRNA-Seq and flow cytometry analysis of the clinical samples. XL, XD, YD, BW, and HL collected the clinical information of the participants. HF and DW performed bioinformatic analysis. All authors participated in writing this paper. HF and DW directly accessed and verifed the underlying data. All authors read and approved the fnal manuscript.

#### **Funding**

This work was supported by the Chinese National Natural Science Foundation Project (Grant numbers 61871382 and 81401635). The funders had no role in the design of the study; collection, analysis, and interpretation of data; writing of the report; or decision to submit the paper for publication.

#### **Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

#### **Declarations**

#### **Ethics approval and consent to participate**

This study was approved by the Eighth Medical Center of the Chinese PLA General Hospital, Beijing, China (ref no. 309202201041537). All experiments and sampling were conducted in accordance with the approved institutional guidelines for ethical and biosafety protocols. Written informed consent was obtained from all participants.

#### **Consent for publication**

Not applicable.

#### **Competing interests**

The authors declare that there are no competing interests.

#### **Author details**

<sup>1</sup>The Eighth Medical Center of Chinese PLA General Hospital, Beijing 100091, People's Republic of China. <sup>2</sup> Emergency Department, Chengde Central Hospital, Chengde 067000, Hebei, People's Republic of China. <sup>3</sup>Institute of Immunology and Molecular Medicine, Jining Medical University, Jining, China.

Received: 29 April 2024 Accepted: 23 July 2024Published online: 10 August 2024

#### **References**

- <span id="page-13-20"></span>Amaral EP, Costa DL, Namasivayam S, Riteau N, Kamenyeva O, Mittereder L, et al. A major role for ferroptosis in *Mycobacterium tuberculosis*-induced cell death and tissue necrosis. J Exp Med. 2019;216:556–70.
- <span id="page-13-25"></span>Bai Y, Hu M, Chen Z, Wei J, Du H. Single-cell transcriptome analysis reveals RGS1 as a new marker and promoting factor for T-cell exhaustion in multiple cancers. Front Immunol. 2021;12:767070.
- <span id="page-13-11"></span>Butler A, Hofman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across diferent conditions, technologies, and species. Nat Biotechnol. 2018;36:411–20.
- <span id="page-13-27"></span>Cai Y, Yang Q, Liao M, Wang H, Zhang C, Nambi S, et al. xCT increases tuberculosis susceptibility by regulating antimicrobial function and infammation. Oncotarget. 2016;7:31001–13.
- <span id="page-13-4"></span>Cai Y, Dai Y, Wang Y, Yang Q, Guo J, Wei C, et al. Single-cell transcriptomics of blood reveals a natural killer cell subset depletion in tuberculosis. EBio-Medicine. 2020;53:102686.
- <span id="page-13-5"></span>Chen P, Wang Y, Li J, Bo X, Wang J, Nan L, et al. Diversity and intratumoral heterogeneity in human gallbladder cancer progression revealed by single-cell RNA sequencing. Clin Transl Med. 2021a;11: e462.
- <span id="page-13-6"></span>Chen W, Liu Z, Zheng Y, Wei B, Shi J, Shao B, et al. Selenium donor restricts the intracellular growth of Mycobacterium tuberculosis through the induction of c-Jun-mediated both canonical autophagy and LC3 associated phagocytosis of alveolar macrophages. Microb Pathog. 2021b;161:105269.
- <span id="page-13-7"></span>Chen Z, Zhao M, Liang J, Hu Z, Huang Y, Li M, et al. Dissecting the single-cell transcriptome network underlying esophagus non-malignant tissues and esophageal squamous cell carcinoma. EBioMedicine. 2021c;69:103459.
- <span id="page-13-24"></span>Feng Z, Zhou J, Liu Y, Xia R, Li Q, Yan L, et al. Epithelium- and endotheliumderived exosomes regulate the alveolar macrophages by targeting RGS1 mediated calcium signaling-dependent immune response. Cell Death Difer. 2021;28:2238–56.
- <span id="page-13-21"></span>Fernandez-Pittol M, Zboromyrska Y, Román A, Benítez MA, Gonzalez-Martin J. Retrospective diagnosis of lymphatic tuberculosis in frozen samples using two genetic amplifcation methods, Xpert® MTB/RIF ULTRA and Abbott RealTime MTB Assay. Rev Esp Quimioter. 2021;34:660–3.
- <span id="page-13-2"></span>Jia H, Pan L, Qin S, Liu F, Du F, Lan T, et al. Evaluation of interferon-γ release assay in the diagnosis of osteoarticular tuberculosis. Diagn Microbiol Infect Dis. 2013;76:309–13.
- <span id="page-13-1"></span>Khan A, Kamra E, Singh R, Sharma V, Singh V, Mor P, et al. Diagnosis of osteoarticular tuberculosis: multi-targeted loop-mediated isothermal amplifcation assay versus multiplex PCR. Future Microbiol. 2021;16:935–48.
- <span id="page-13-19"></span>Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12:599–620.
- <span id="page-13-26"></span>Lang X, Green MD, Wang W, Yu J, Choi JE, Jiang L, et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9:1673–85.
- <span id="page-13-14"></span>Liu Z, Zhou G, Deng X, Yu Q, Hu Y, Sun H, et al. Analysis of miRNA expression profling in human macrophages responding to Mycobacterium infection: induction of the immune regulator miR-146a. J Infect. 2014;68:553–61.
- <span id="page-13-9"></span>Macosko EZ, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M, et al. Highly parallel genome-wide expression profling of individual cells using nanoliter droplets. Cell. 2015;161:1202–14.
- <span id="page-13-17"></span>Nguyen TKT, Niaz Z, d'Aigle J, Hwang SA, Kruzel ML, Actor JK. Lactoferrin reduces mycobacterial M1-type infammation induced with trehalose 6,6′-dimycolate and facilitates the entry of fuoroquinolone into granulomas. Biochem Cell Biol. 2021;99:73–80.
- <span id="page-13-23"></span>Patel J, McNeill E, Douglas G, Hale AB, de Bono J, Lee R, et al. RGS1 regulates myeloid cell accumulation in atherosclerosis and aortic aneurysm rupture through altered chemokine signalling. Nat Commun. 2015;6:6614.
- <span id="page-13-18"></span>Ren J, Han X, Lohner H, Liang R, Liang S, Wang H. Serum- and glucocorticoidinducible kinase 1 promotes alternative macrophage polarization and restrains infammation through FoxO1 and STAT3 signaling. J Immunol. 2021;207:268–80.
- <span id="page-13-10"></span>Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33:495–502.
- <span id="page-13-0"></span>Sharma SK, Mohan A, Kohli M. Extrapulmonary tuberculosis. Expert Rev. Respir Med. 2021;15:931–48.
- <span id="page-13-3"></span>Singhania A, Dubelko P, Kuan R, Chronister WD, Muskat K, Das J, et al. CD4+CCR6+ T cells dominate the BCG-induced transcriptional signature. EBioMedicine. 2021;74:103746.
- <span id="page-13-22"></span>Sun T, Wu B, Luo Z, Wang J, Deng S, Huang Q. Cell population data in identifying active tuberculosis and community-acquired pneumonia. Open Med. 2021;16:1143–9.
- <span id="page-13-8"></span>Wang L, Shang X, Qi X, Ba D, Lv J, Zhou X, et al. Clinical signifcance of M1/M2 macrophages and related cytokines in patients with spinal tuberculosis. Dis Markers. 2020;2020:2509454.
- <span id="page-13-13"></span>Wang D, Lin Y, Xu F, Zhang H, Zhu X, Liu Z, et al. SIRPα maintains macrophage homeostasis by interacting with PTK2B kinase in *Mycobacterium tuberculosis* infection and through autophagy and necroptosis. EBioMedicine. 2022;85:104278.
- <span id="page-13-12"></span>Zhang YX, Wang SN, Chen J, Hu JG, Lü HZ. A transcriptomic study of probenecid on injured spinal cords in mice. PeerJ. 2020;8: e8367.
- <span id="page-13-15"></span>Zhou CX, Li L, Ma YG, Li BN, Li G, Zhou Z, et al. A bioactive implant in situ and long-term releases combined drugs for treatment of osteoarticular tuberculosis. Biomaterials. 2018;176:50–9.
- <span id="page-13-16"></span>Zou Q, Lv Y, Gan Z, Liao S, Liang Z. Identifcation and validation of a malignant cell subset marker-based polygenic risk score in stomach adenocarcinoma through integrated analysis of bulk and single-cell RNA sequencing data. Front Cell Dev Biol. 2021;9:720649.

## **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afliations.